Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer. Metastatic means the cancer ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that patients won't see these numbers and just throw up their hands in fear or resignation.

"Prostate cancer is a worldwide problem. It is the most common cancer in men, with clear racial disparities,” said researcher ...

Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Insights from AUA 2025, including anticipated presentations, key takeaways, and how new research in metastatic prostate ...

Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.

The treatment of metastatic castration-resistant prostate cancer ... With appropriate treatment, people with this advanced ...